SCHEMBL25035641

SCHEMBL25035641

CC(C)n1c(=O)c(-c2cc(F)c(NS(=O)(=O)CC3CC(F)(F)C3)c(F)c2)nc2cnc(N)nc21

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 3/20 0.52
BRAF P15056 1/20 0.35
CYP1A2 P05177 9/20 0.34
ALDH1A1 P00352 8/20 0.34
HSD17B10 Q99714 6/20 0.34
CASP1 P29466 5/20 0.34
CASP7 P55210 5/20 0.34
USP2 O75604 5/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
HIF1A Q16665 2/20 0.34
GLA P06280 2/20 0.34
CLK4 Q9HAZ1 1/20 0.34
MTOR P42345 4/20 0.33
RORC P51449 2/20 0.33
LMNA P02545 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 2/20 0.31
CYP3A4 P08684 2/20 0.31
TLR9 Q9NR96 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25034134 0.90 ERN1 (0.50) ERN1BRAFCYP1A2ALDH1A1HSD17B10
SCHEMBL25035522 0.88 ERN1 (0.53) ERN1BRAFCYP1A2ALDH1A1HSD17B10
SCHEMBL25034135 0.85 ERN1 (0.50) ERN1BRAFCYP1A2ALDH1A1HSD17B10
SCHEMBL22200786 0.84 ERN1 (0.43) ERN1CYP1A2ALDH1A1HSD17B10CASP1
SCHEMBL25035539 0.84 ERN1 (0.54) ERN1BRAFCYP1A2ALDH1A1HSD17B10
SCHEMBL25034233 0.84 ERN1 (0.48) ERN1BRAFCYP1A2ALDH1A1HSD17B10
SCHEMBL22200505 0.83 ERN1 (0.76) ERN1CYP1A2ALDH1A1HSD17B10CASP1
SCHEMBL22190703 0.83 ERN1 (0.76) ERN1CYP1A2ALDH1A1HSD17B10CASP1
SCHEMBL29356247 0.83 ERN1 (0.76) ERN1CYP1A2ALDH1A1HSD17B10CASP1
SCHEMBL25034136 0.83 ERN1 (0.70) ERN1BRAFCYP1A2ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230047209-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE PARAZA PHARMA, INC. (CA) 2023-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230047209-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE TYMP, TYMS, DPYD ERN1 3167/4885BRAF 563/4885CYP1A2 1312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.